B-cell Translocation Gene 2 Inhibits The Proliferation And Migration Of Human Ovarian Cancer Cells In Vitro

Background: Ovarian cancer is one of the gynecological malignancies.The incidence of ovarian cancer ranks the third in the gynecologic tumor after cervical cancer and uterine cancer,however,ovarian cancer is the most lethal gynecologic malignancy.Due to the poor early diagnosis and high metastasis and recurrence rate,the five-year survival rate of ovarian cancer has been below 40% in the decades.The current clinical treatment of ovarian cancer is cyto-reduction surgery,supplemented by postoperative radiotherapy,chemotherapy and biotherapy.Chemotherapy is the effective treatment among those.About 75% of ovarian cancer patients are diagnosed with ovarian cancer at a later stage,and the survival rate of patients with advanced ovarian cancer is very low.So we need to find new treatments and new tumor therapeutic targets to conquer ovarian cancer.BTG2(B-cell translocation gene 2)is a member of BTG/TOB anti-proliferative protein family.BTG2 could inhibit cell proliferation and migration and regulate the cell cycle progression.Therefore,BTG2 may be a target in tumor treatment.Objective: This research mainly studies the effects of BTG2 on proliferation,migration,cell cycle and cisplatin resistance in ovarian cancer cells and the underlying mechanism.The study provides a new target to cure ovarian cancer.Methods: 1.The m RNA expression of BTG2 in normal ovarian tissues and ovarian cancer tissues and 5-year survival rate of patients with different BTG2 expression were detected by bioinformatics methods.2.The expression of BTG2 in ovarian cancer cell or tissue was analyzed using Real-time q PCR.3.Ovarian cancer cells were transfected with BTG2 expression plasmid and sh RNA plasmids by lipofectamin2000,stable-expression monoclonal cell lines were got after culturing with G418.4.Cell survival and proliferation were evaluated using MTT assay and colony formation.5.The cell cycle was detected by flow cytometry.6.Using transwell chamber assay to detect the migration ability of ovarian cells.7.The expression of BTG2 in ovarian cancer cells was analyzed using Western Blotting.Results: 1.BTG2 m RNA was low-expressed in human ovarian cancer samples and that BTG2 low-expression correlated with the shortened survival time of ovarian cancer patients.2.Results showed that the expression of BTG2 was more in normal ovarian tissues than ovarian cancer tissues.3.MTT and clone formation experiments show that high BTG2 gene expression can restrain the growth of the ovarian tumor cells and proliferation.4.Flow cytometry revealed that high expression of BTG2 could induce G1/S arrest in ovarian cancer cells.5.Transwell chamber assays showed that BTG2 suppressed the migration of ovarian cancer cells.6.Western blotting showed that upregulation of BTG2 suppressed the expression of Cyclin D1 and CDK4.And BTG2 inhibited the expression of MMP-2 and MMP-9.7.Cisplatin enhanced the m RNA and protein expression level of BTG2 in a dose-dependent manner.Conclusion: BTG2 inhibits ovarian cancer cell proliferation and migration,blocks ovarian cancer cell cycle,enhances cisplatin sensitivity of ovarian cancer cells,suggesting that BTG2 could be used as a target of ovarian cancer treatment.